Compare Lloyds Banking Group Plc American Depositary Shares (LYG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lloyds Banking Group Plc American Depositary Shares vs Organon & Co. Common Stock — how do they compare? Lloyds Banking Group Plc American Depositary Shares trades at $5.55 (market cap $79.07B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Lloyds Banking Group Plc American Depositary Shares is far larger — about 21.8× Organon & Co. Common Stock's market cap, and Lloyds Banking Group Plc American Depositary Shares pays the higher dividend (3.96%). Which is the better fit depends on your goals — on Pluang, investors hold Lloyds Banking Group Plc American Depositary Shares for 3 Days and Organon & Co. Common Stock for 0 Days on average.
| LYG | OGN | |
|---|---|---|
Market Cap | $79.07B | $3.62B |
Volume | 20,385,611 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $6.28 | $13.81 |
52-Week Low | $4.44 | $5.70 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $101.61B | $11.04B |
Dividend Yield | 3.96% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lloyds Banking Group (LYG) trades at $5.50, up 0.73% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 24.5% and has beaten earnings estimates in two of the last three quarters. Recent news highlights its 2030 growth plan emphasizing AI and efficiency, with potential acquisition interest in Aldermore.
The outlook is mixed: analyst consensus is bullish (58% buy ratings), but technicals and a recent earnings miss pose near-term risks. Upside catalysts include strategic investments and resilient UK consumers, while risks involve economic sensitivity and competitive pressures. The stock's valuation appears reasonable with a P/E of 12.98.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Lloyds Banking Group Plc American Depositary Shares
Lloyds Banking Group provides retail, commercial, and insurance services in the United Kingdom. Its banking brands include Lloyds Bank, Halifax, and Bank of Scotland.
Read more on LYG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
